Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo?

Trends in Immunology

Volumn 29, Issue 6, 2008, Pages 280-289

  Bosch, Xavier ^a   Guilabert, Antonio ^a   Espinosa, Gerard ^a   Mirapeix, Eduard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; DRUG EFFECT; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW; SURVIVAL;

EID: 44549085005     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2008.03.001     Document Type: Review

References (95)

1. Jennette J.C., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 37 (1994) 187-192
2. Seo P., and Stone J.H. The antineutrophil cytoplasmic antibody-associated vasculitides. Am. J. Med. 117 (2004) 39-50
3. Jennette J.C., and Falk R.J. Small-vessel vasculitis. N. Engl. J. Med. 337 (1997) 1512-1523
4. Bosch X., et al. Antineutrophil cytoplasmic antibodies. Lancet 368 (2006) 404-418
5. Kallenberg C.G., et al. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat. Clin. Pract. Rheumatol. 2 (2006) 661-670
6. Pagnoux C., et al. Churg-Strauss syndrome. Curr. Opin. Rheumatol. 19 (2007) 25-32
7. Bosch X., et al. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 298 (2007) 655-669
8. Booth A., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 15 (2004) 717-721
9. Langford C.A. Treatment of ANCA-associated vasculitis. N. Engl. J. Med. 349 (2003) 3-4
10. Hellmich B., et al. Advances in the therapy of Wegener's granulomatosis. Curr. Opin. Rheumatol. 18 (2006) 25-32
11. Sarraf P., et al. Wegener's granulomatosis: is biologic therapy useful?. Curr. Rheumatol. Rep. 8 (2006) 303-311
12. Bacon P.A. The spectrum of Wegener's granulomatosis and disease relapse. N. Engl. J. Med. 352 (2005) 330-332
13. Sarraf P., and Sneller M.C. Pathogenesis of Wegener's granulomatosis: current concepts. Expert Rev. Mol. Med. 7 (2005) 1-19
14. Pfister H., et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104 (2004) 1411-1418
15. Specks U. Are animal models of vasculitis suitable tools?. Curr. Opin. Rheumatol. 12 (2000) 11-19
16. Lamprecht P., et al. Current state of biologicals in the management of systemic vasculitis. Ann. N. Y. Acad. Sci. 1110 (2007) 261-270
17. Voswinkel J., et al. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann. N. Y. Acad. Sci. 1051 (2005) 12-19
18. Lamprecht P., et al. CD28- T cells display features of effector memory T cells in Wegener's granulomatosis. Kidney Int. 65 (2004) 1113
19. Komocsi A., et al. Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis. Am. J. Pathol. 160 (2002) 1717-1724
20. Csernok E., et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum. 42 (1999) 742-750
21. Lamprecht P., et al. Differences in CCR5 expression on peripheral blood CD4+CD28- T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin. Immunol. 108 (2003) 1-7
22. Appay V., et al. Characterization of CD4(+) CTLs ex vivo. J. Immunol. 168 (2002) 5954-5958
23. Abdulahad W.H., et al. CD4-positive effector memory T cells participate in disease expression in ANCA-associated vasculitis. Ann. N. Y. Acad. Sci. 1107 (2007) 22-31
24. Voswinkel J., et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann. Rheum. Dis. 65 (2006) 859-864
25. Preston G.A., et al. New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: the theory of autoantigen complementarity. Curr. Opin. Nephrol. Hypertens. 14 (2005) 217-222
26. Falk R.J., et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 4115-4119
27. Jennette J.C., et al. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J. Am. Soc. Nephrol. 17 (2006) 1235-1242
28. Kallenberg C.G. Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Curr. Opin. Rheumatol. 19 (2007) 17-24
29. Savage C.O., et al. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am. J. Pathol. 141 (1992) 335-342
30. Ewert B.H., et al. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int. 41 (1992) 375-383
31. Schreiber A., et al. Membrane expression of proteinase 3 is genetically determined. J. Am. Soc. Nephrol. 14 (2003) 68-75
32. Morgan M.D., et al. Anti-neutrophil cytoplasm-associated glomerulonephritis. J. Am. Soc. Nephrol. 17 (2006) 1224-1234
33. Calderwood J.W., et al. ANCA induces beta2 integrin and CXC chemokine-dependent neutrophil-endothelial cell interactions that mimic those of highly cytokine-activated endothelium. J. Leukoc. Biol. 77 (2005) 33-43
34. Tse W.Y., et al. ANCA-induced neutrophil F-actin polymerization: implications for microvascular inflammation. Kidney Int. 67 (2005) 130-139
35. Day C.J., et al. New developments in the pathogenesis of ANCA-associated vasculitis. Clin. Exp. Rheumatol. 21 (2003) S35-S48
36. Csernok E. Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides. Autoimmun. Rev. 2 (2003) 158-164
37. Moosig F., et al. Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-alpha (TNF-alpha). Clin. Exp. Immunol. 122 (2000) 499-503
38. Xiao H., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110 (2002) 955-963
39. Huugen D., et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am. J. Pathol. 167 (2005) 47-58
40. Xiao H., et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am. J. Pathol. 167 (2005) 39-45
41. Xiao H., et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 170 (2007) 52-64
42. Huugen D., et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 71 (2007) 646-654
43. Little M.A., et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106 (2005) 2050-2058
44. Bansal P.J., and Tobin M.C. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann. Allergy Asthma Immunol. 93 (2004) 398-401
45. Schlieben D.J., et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCA. Am. J. Kidney Dis. 45 (2005) 758-761
46. Noronha I.L., et al. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int. 43 (1993) 682-692
47. Tesar V., et al. Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol. Dial. Transplant. 13 (1998) 1662-1667
48. Knight D.M., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30 (1993) 1443-1453
49. Mukhtyar C., and Luqmani R. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Ann. Rheum. Dis. 64 Suppl 4 (2005) iv31-iv36
50. Booth A.D., et al. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann. Rheum. Dis. 61 (2002) 559
51. Bartolucci P., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxf) 41 (2002) 1126-1132
52. Lamprecht P., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxf) 41 (2002) 1303-1307
53. Stone J.H., et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 44 (2001) 1149-1154
54. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. (2005) Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351-361
55. Stone J.H., et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 54 (2006) 1608-1618
56. Akobeng A.K., and Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2004 (2004) CD003574
57. Sandborn W.J., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
58. Scallon B., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301 (2002) 418-426
59. Mitoma H., et al. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology 126 (2004) 934-935
60. Van den Brande J.M., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
61. Flossmann O., et al. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?. Ann. Rheum. Dis. 65 (2006) 841-844
62. Sneller M.C. Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment?. Arthritis Rheum. 52 (2005) 1-5
63. Popa E.R., et al. Differential B- and T-cell activation in Wegener's granulomatosis. J. Allergy Clin. Immunol. 103 (1999) 885-894
64. Brihaye B., et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin. Exp. Rheumatol. 25 (2007) S23-S27
65. Tamura N., et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern. Med. 46 (2007) 409-414
66. Aries P.M., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. 65 (2006) 853-858
67. Keogh K.A., et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 173 (2006) 180-187
68. Smith K.G., et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 54 (2006) 2970-2982
69. Stasi R., et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45 (2006) 1432-1436
70. Keogh K.A., et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52 (2005) 262-268
71. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. 257 (2005) 540-548
72. Omdal R., et al. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand. J. Rheumatol. 34 (2005) 229-232
73. Golbin J.M., and Specks U. Part 2: Synopsis of B-lymphocyte targeted therapy of ANCA-associated vasculitis. Clin. Exp. Rheumatol. 25 (2007) S74-S76
74. Eisenberg R., and Looney R.J. The therapeutic potential of anti-CD20 "what do B-cells do?. Clin. Immunol. 117 (2005) 207-213
75. Gross W.L. Churg-Strauss syndrome: update on recent developments. Curr. Opin. Rheumatol. 14 (2002) 11-14
76. Tatsis E., et al. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann. Intern. Med. 129 (1998) 370-374
77. Simon H.U., et al. Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. Allergy 58 (2003) 1250-1255
78. Termeer C.C., et al. Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement. Arch. Dermatol. 137 (2001) 136-138
79. Genovese M.C., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353 (2005) 1114-1123
80. Abrams J.R., et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192 (2000) 681-694
81. Vincenti F., et al. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353 (2005) 770-781
82. Zhou Y., et al. An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum. 50 (2004) 2645-2650
83. Hewins P., et al. IL-18 is upregulated in the kidney and primes neutrophil responsiveness in ANCA-associated vasculitis. Kidney Int. 69 (2006) 605-615
84. Schonermarck U., et al. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin. Exp. Rheumatol. 18 (2000) 457-463
85. Hellmich B., et al. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann. N. Y. Acad. Sci. 1051 (2005) 121-131
86. Walsh M., and Jayne D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int. 72 (2007) 676-682
87. Krumbholz M., et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J. Autoimmun. 25 (2005) 298-302
88. Trendelenburg M. Complement inhibition by anti-C5 antibodies-from bench to bedside and back again. Swiss Med. Wkly. 137 (2007) 413-417
89. Selamet U., et al. ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs. Expert Opin. Investig. Drugs 16 (2007) 689-703
90. Csernok E., et al. Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood 107 (2006) 4440-4448
91. Rarok A.A., et al. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J. Leukoc. Biol. 74 (2003) 3-15
92. Williams J.M., and Savage C.O. Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies. J. Am. Soc. Nephrol. 16 (2005) 90-96
93. Williams J.M., et al. Antineutrophil cytoplasm antibody-stimulated neutrophil adhesion depends on diacylglycerol kinase-catalyzed phosphatidic acid formation. J. Am. Soc. Nephrol. 18 (2007) 1112-1120
94. Marinaki S., et al. Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis. Nephrol. Dial. Transplant. 21 (2006) 1825-1832
95. Ruth A.J., et al. Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. J. Am. Soc. Nephrol. 17 (2006) 1940-1949